Industry
Featured experience
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Haleon $3.1 billion secondary offering
The shares are listed on the NYSE
Smith+Nephew $1 billion notes offering
We advised the issuer on the SEC-registered offering
Avid Bioservices $160 million convertible senior notes offering
The convertible notes are due 2029
REGENXBIO $140 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
iRhythm Technologies $661.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
Roche Holdings $3.875 billion notes offering
We advised Roche on the Rule 144A / Regulation S offering comprising four tranches of notes
Tandem Diabetes Care $316.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
LivaNova $345 million convertible notes offering and capped call transactions
The 2.5% convertible senior notes are due 2029
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches